• 
• 
• 

FDA News and Drug Updates

Government Shutdown Impacts FDA Drug Approvals

Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation

FDA Approves 2 New Biosimilars for Patients with Cancer

FDA News - September 2018

Adverse Effects

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Adverse Events Associated with Checkpoint Inhibitors

Alice Goodman

View All Supportive Care Articles

Immunotherapy

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Building on the Successes of Cancer Immunotherapy

Charles Bankhead

View All Breast Cancer Articles

Conference Correspondent

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference

Silent Patients Find Their Voices Through an Advocate’s Journey

View All Conference Correspondent Articles

Most Popular Articles

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

JHOP Web Exclusives - Colorectal Cancer, Immunotherapy

Building on the Successes of Cancer Immunotherapy

Charles Bankhead

JHOP Web Exclusives - Immunotherapy

Oral Toxicities Associated with Cancer Therapies: What's Old Is New Again

Meg Barbor, MPH

JHOP Web Exclusives - Drug Therapies

Managing Bone Metastases Through a Multidisciplinary Approach

Meg Barbor, MPH

JHOP Web Exclusives - Supportive Care

Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation

JHOP Web Exclusives - FDA Approvals, News & Updates